Some mRCC patients miss out on molecular era benefits
Researchers report that certain subgroups of Japanese patients with metastatic renal cell carcinoma fare no better since the introduction of molecular-targeted therapies than patients treated with cytokine-based immunotherapy alone.
Source: MedWire News - Urology - Category: Urology & Nephrology Source Type: news
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology